Healthcare Press

Alzheimer’s Treatment Thrills Investors as Doctors Debate Effect

  • 📰 WSJ
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Heard on the Street: Results from Elsai's experimental Alzheimer’s treatment thrilled investors, but doctors are still debating

Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease.

WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet. Illustration: Jacob ReynoldsIn a press release in late September announcing that Eisai’s experimental Alzheimer’s drug

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Pricing is expected to be a major issue in future.

It’s a terrible me too product that DOES NOT OFFER ANYTHING NEW to the AZ market. Stop it. Do better Eisai

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Drug abuse treatment facility will pay $3M to resolve role in kickback schemeThe facility was accused of causing kickbacks, obstructing a federal audit, and fraudulently billing Medicaid, authorities said.
Source: njdotcom - 🏆 282. / 63 Read more »